Pharmalittle: Lilly Deal, Intellia CRISPR Treatment
Fast facts
- Category: Health
- Language: EN
- Published: 2026-04-27 09:18 UTC
- Sources: Stat News
In today's Pharmalittle, we're reading about a deal between Lilly and another company, as well as Intellia's progress with its CRISPR therapy for hereditary angioedema. Meanwhile, Astellas is re-entering the clinic with a new gene therapy.
Why it matters
- This update can influence the Health agenda over the next 24-48 hours.
- It is based on 1 source, which helps cross-check key claims quickly.
- Watch follow-up statements and market/public response to assess real impact.